Related references
Note: Only part of the references are listed.Management of Patients With Treatment-Resistant Depression
Michael E. Thase
JOURNAL OF CLINICAL PSYCHIATRY (2009)
Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder
Michael R. Liebowitz et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Comparative Risk for Harms of Second-Generation Antidepressants A Systematic Review and Meta-Analysis
Gerald Gartlehner et al.
DRUG SAFETY (2008)
Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial
Patrice Boyer et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2008)
A pooled analysis of two placebo-controlled trials of desvenlafaxine in major depressive disorder
Daniel Z. Lieberman et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2008)
The prevention of recurrent episodes of depression with venlafaxine for two years (PREVENT) study: Outcomes from the acute and continuation phases
Martin B. Keller et al.
BIOLOGICAL PSYCHIATRY (2007)
A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder
Michael R. Liebowitz et al.
JOURNAL OF CLINICAL PSYCHIATRY (2007)
Changes in sexual functioning associated with duloxetine, escitalopram, and placebo in the treatment of patients with major depressive disorder
Anita Clayton et al.
JOURNAL OF SEXUAL MEDICINE (2007)
Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder
Teresa A. Pigott et al.
CURRENT MEDICAL RESEARCH AND OPINION (2007)
Escitalopram maintenance treatment for prevention of recurrent depression: A randomized, placebo-controlled trial
Susan G. Kornstein et al.
JOURNAL OF CLINICAL PSYCHIATRY (2006)
Tolerability and safety of fluvoxamine and other antidepressants
HGM Westenberg et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2006)
Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: A meta-analysis of original data from 7 randomized controlled trials
ME Thase et al.
JOURNAL OF CLINICAL PSYCHIATRY (2005)
Continuity is the main challenge in treating major depressive disorder in psychiatric care
TK Melartin et al.
JOURNAL OF CLINICAL PSYCHIATRY (2005)
Comparison of the effects of mirtazapine and fluoxetine in severely depressed patients
M Versiani et al.
CNS DRUGS (2005)
SNRIs: The pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants
SM Stahl et al.
CNS SPECTRUMS (2005)
Which factors influence psychiatrists' selection of antidepressants?
M Zimmerman et al.
AMERICAN JOURNAL OF PSYCHIATRY (2004)
Mirtazapine orally disintegrating tablet versus sertraline:: A prospective onset of action study
K Behnke et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2003)
Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review
JR Geddes et al.
LANCET (2003)
Prevalence of sexual dysfunction among newer antidepressants
AH Clayton et al.
JOURNAL OF CLINICAL PSYCHIATRY (2002)
Duloxetine in the treatment of major depressive disorder: A double-blind clinical trial
DJ Goldstein et al.
JOURNAL OF CLINICAL PSYCHIATRY (2002)
Fluoxetine versus sertraline and paroxetine in major depressive disorder: Changes in weight with long-term treatment
M Fava et al.
JOURNAL OF CLINICAL PSYCHIATRY (2000)
Randomized, double-blind comparison of venlafaxine and sertraline in outpatients with major depressive disorder
OP Mehtonen et al.
JOURNAL OF CLINICAL PSYCHIATRY (2000)
Share Paper
